Vera Therapeutics Secures FDA Priority Review for Atacicept with July 2026 PDUFA Date, Bolstered by Strong Phase 3 Data and Extended Cash Runway

summarizeSummary

Vera Therapeutics announced FDA priority review for its atacicept BLA with a July 2026 PDUFA date, following positive Phase 3 data, and confirmed sufficient funding for its anticipated mid-2026 commercial launch.

check_boxKey Events

• FDA Grants Priority Review for Atacicept BLA

  The U.S. Food and Drug Administration (FDA) granted priority review to the Biologics License Application (BLA) for atacicept for the treatment of IgA nephropathy (IgAN) in adults, setting a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026.

• Positive Phase 3 Data Published

  Positive primary endpoint results from the ORIGIN Phase 3 clinical trial of atacicept were presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, demonstrating clinically meaningful reductions in proteinuria.

• Strong Financial Position and Extended Cash Runway

  Vera Therapeutics reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025. Combined with availability under its debt facility, the company believes this is sufficient to fund operations beyond potential approval and U.S. commercial launch of atacicept, following $800 million in equity and debt financings in 2025.

• Anticipates Mid-2026 Commercial Launch

  The company is advancing preparations for a potential U.S. commercial launch of atacicept in mid-2026, pending FDA approval, and has appointed James R. Meyers to its Board of Directors to support commercial leadership.

auto_awesomeAnalysis

This filing is highly significant for Vera Therapeutics as it confirms the FDA has granted priority review for atacicept's Biologics License Application (BLA) for IgA nephropathy (IgAN), setting a PDUFA date of July 7, 2026. This accelerates the potential approval timeline and signals a major step towards commercialization. The company also reported positive Phase 3 data published in the New England Journal of Medicine and a strong balance sheet, including $800 million in 2025 financing, which is expected to fund operations beyond the potential approval and U.S. commercial launch. While the net loss increased in 2025, the substantial progress in clinical development and regulatory review, coupled with a solid financial runway, significantly de-risks the company's lead asset and future prospects.